TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of Multiple Myeloma~* Patients intended to be treated with myeloablative therapy and autologous hematopoetic stem-cell transplant within one month of stem-cell collection~* Patients whose stem-cell mobilization regimen includes G-CSF (granulocyte-colony stimulating factor)~* Males or non-pregnant females, who are 18 years of age or older~* Karnofsky score of ≥70%~Exclusion Criteria:~* Patients with pre-mobilization platelet count \< 75,000/µL~* Patients who have received pelvic bone marrow irradiation as part of their conditioning therapy~* Patients who have had a previous hematopoetic stem-cell transplant~* Patients who have had a previous hematopoetic stem-cell collection failure~* Impaired cardiac function, as evidenced by left ventricular ejection fraction \<40%.~* Impaired hepatic function, as evidenced by alanine transaminase \>2.5 x normal~* Impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon monoxide (adjusted for patient hematocrit, if indicated) or forced expiratory volume in 1 second \<50% of predicted~* Impaired renal function, as evidenced by a creatinine clearance \< 40 mL/min~* Impaired coagulation, as evidenced by a prothrombin time (PT) \> twice normal~* Pregnancy or lactation~* Seropositivity for Human Immunodeficiency Virus-1/2, Hepatitis B Virus, or Hepatitis C Virus~* Documented bacterial or fungal infection that requires intravenous antibiotics to be started or continued while undergoing apheresis collection on the Spectra Optia device~* Subjects enrolled in study protocols that could affect number of CD34+ cells (pluripoten hematopoetic stem stells) collected or kinetics of neutrophil recovery~* Altered mental status, as evidenced by the inability to provide effective informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with multiple myeloma (Type: EXPERIMENTAL): Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:~* Age ≥ 75, previous stroke~* transient ischemic attack (TIA) or Systemic Embolism (SE)~* Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40%~* Diabetes mellitus or hypertension requiring pharmacological treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aerobic Exercise in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran or non-veteran;~* Presence of all 3 cardinal features of Parkinson's disease (resting tremor, bradykinesia, and rigidity), which have to be asymmetrical;~* Hoehn and Yahr Scale stage I-III;~* Men or women aged 50-80 capable of performing the planned exercise programs;~* Intention to remain in the local area over the study period;~* Stable dopaminergic treatment regimen for at least 4 weeks prior to baseline without any clinical need for medication adjustment at the time of screening~Exclusion Criteria:~* Secondary parkinsonism;~* Parkinson-plus syndromes;~* MMSE score \<24;~* Participating in a aerobic exercise program;~* An unstable dosage of drugs active in the central nervous system (e.g., anxiolytics, antidepressants) during the 60 days before the baseline visit;~* Participation in drug studies or the use of investigational drugs within 30 days before screening; structural brain disease;~* Active epilepsy;~* Acute illness or active, confounding medical, neurological, or musculoskeletal conditions; alcoholism or other forms of drug addiction;~* Inability to complete the graded exercise test;~* Lack of medical clearance from our pulmonologist;~* Intention to move or take a \>1 month vacation during the study period;~* Contraindications to MRI or claustrophobia requiring sedation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Continuous training (Type: ACTIVE_COMPARATOR): Aerobic walking using continuous heart rate training.
- Interval training (Type: ACTIVE_COMPARATOR): Aerobic walking using interval heart rate training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Vasopressin, Methylprednisolone, and Epinephrine for Inhospital Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult in-patients with cardiac arrest requiring epinephrine according to current guidelines.~Exclusion Criteria:~* Age \< 18 years.~* Documented terminal illness (life expectancy \< 6 weeks).~* Do not resuscitate status.~* Cardiac arrest before arrival at hospital.~* Prior enrollment into the study (i.e. second or third inhospital arrest etc.).~* Corticosteroid treatment before the cardiac arrest.~* Any inaccurate documentation of CPR data such as medication, number of countershocks etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
- Study Group (Type: EXPERIMENTAL): Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of seasonal allergic rhinitis from grass pollen~* Normal electrocardiogram~* Moderate to severe response to approx. 1500 grass pollen grains/m3 after 2 hrs of exposure in challenge chamber~* Positive skin prick test for grass pollen at or within 12 months preceding screening visit~* Positive RAST (class 2 or higher) for timothy grass pollen and to rPhl p 1 + rPhl p 5 at or within 12 months preceding screening visit~Exclusion Criteria:~* Pregnant or lactating females~* Females with childbearing potential not using medically acceptable birth control~* Structural nasal abnormalities, nasal polyposis, history of frequent nosebleeds, recent nasal surgery or ongoing upper respiratory tract infection~* Any respiratory disease other than mild asthma controlled with occasional short acting beta agonists and normal lung function~* Current or recent participation in another clinical trial~* SIT for grass pollen allergy in the last two years prior to study~* Past or present disease, which may affect outcome of the trial, judged by investigator~* Autoimmune diseases, immune defects including immunosuppression, immune- complex immunopathies~* Suspected hypersensitivity to any ingredients of study medication~* Use of prohibited medication prior to screening and throughout study~* depot corticosteroids (12 weeks)~* oral corticosteroids (8 weeks)~* inhaled corticosteroids (4 weeks)~* Allergic symptoms at the time of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BM32 low dose (Type: EXPERIMENTAL): 3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
- BM32 medium dose (Type: EXPERIMENTAL): 3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
- BM32 high dose (Type: EXPERIMENTAL): 3 subcutaneous injections of BM32 over a time span of 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 3 subcutaneous injections over a time span of 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of 6 months to 18 years of age~* Presenting for emergency treatment within 5 hours with clinically important systemic signs of scorpion sting envenomation.~* Signed written Informed Consent by patient or legal guardian.~* No participation in a clinical drug trial within the last month or concomitantly.~Exclusion Criteria:~* Allergy to horse serum.~* Use within the past 24 hours of drugs expected to alter immune response: H1 or H2 blockers, corticosteroids.~* Use of any antivenom within the last month or concomitantly.~* Underlying medical conditions that significantly alter immune response: bone marrow suppression congenital or acquired immuno-deficiency state, chemotherapy and chronic corticosteroid use.~* Allergy to midazolam.~* More than 0.3mg/kg of body weight of midazolam administered during the hour prior to study drug infusion.~* Concurrent medical condition involving a baseline neurologic status mimicking envenomation (chorea, tardive dyskinesia, uncontrolled epilepsy).~* Pregnant and nursing women.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Alacramyn and midazolam as needed
- 2 (Type: PLACEBO_COMPARATOR): placebo and midazolam as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has provided written informed consent~2. Has adenocarcinoma of the colon or rectum~3. Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer~4. ECOG performance status of 0 or 1~5. Is able to take medications orally~6. Has adequate organ function (bone marrow, kidney and liver)~7. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.~Exclusion Criteria:~1. Certain serious illnesses or medical condition(s)~2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration~3. Has received TAS-102~4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies~5. Is a pregnant or lactating female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-102 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of Autism Spectrum Disorder.~* Have social anxiety.~* Are at least 21 years old.~* Have completed two years of college-level education or comparable vocational training.~* Are willing to refrain from psychiatric medication for at least 5 half-lives plus a week prior to experimental session.~* Agree to follow all study-related instructions and restrictions, including restrictions on food, alcohol and caffeine consumption prior to experimental sessions.~* Are willing to commit to preparatory sessions, medication management, experimental sessions, follow-up sessions and to complete evaluation instruments.~* Agree not to use MDMA/ecstasy outside of study sessions during the study, including the follow up period.~* Are willing to be contacted on a daily basis for a week after each experimental session.~* Are willing to provide a contact that is willing and able to be reached by investigators, accompany the subject during some or all of the study visits, and complete study measures.~* Are willing to give blood samples.~* Are proficient in speaking and reading English. Subjects communicating with text-to-speech technology will also be permitted to enroll.~Exclusion Criteria:~* Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.~* Are abusing illegal drugs.~* Are not able to give adequate informed consent.~* Are not able to attend face-to-face visits or those who plan to move out of the area within the treatment period.~* Are pregnant or nursing, or if are able to bear children and do not practice an effective means of birth control.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inactive Placebo with Therapy (Type: PLACEBO_COMPARATOR): Participants will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
- Group 1: MDMA-assisted therapy 75 mg/100mg (Type: EXPERIMENTAL): Participants will receive 75 mg and 100 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.
- Group 2: MDMA-assisted therapy 100 mg/125 mg (Type: EXPERIMENTAL): Participants will receive 100 mg and 125 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than or equal to 18 years.~2. Ability to provide informed consent or assent.~3. Prior successful participation in a tolvaptan hyponatremia trial termination with evidence of continued need or desire for therapy.~Exclusion Criteria:~* A current medical condition where long-term treatment with an aquaretic agent may present an undue risk to the patient.~* Hyponatremia which is acute, reversible, artifactual or due to conditions not associated with vasopressin excess or likely to respond to aquaretic therapy.~* Hyponatremia due to reversible medical condition or therapy~* Conditions associated with an independent imminent risk of morbidity and mortality~* Conditions which confound the assessment of endpoints.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers willing to have 2 consecutive finger sticks completed.~Exclusion Criteria:~* Participants are excluded if they have a history of drug induced hypersensitivity reactions; took any anti-inflammatory medications in the past 12 hours; if they routinely performed finger lancing for blood specimen monitoring (e.g. diabetes); or had calloused fingers pads.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 5% Loperamide gel (Type: EXPERIMENTAL): Participants received 5% loperamide gel (0.2gm equivalent to 10 mg) applied following a single surgilance to the 5th digit. The loperamide gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the loperamide gel which was left in place for 30 minutes. The placebo gel contained the same ingredients without the loperamide. The loperamide gel formulation includes: Loperamide 5%, Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
- Placebo gel (Type: PLACEBO_COMPARATOR): Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1. Documented histologically confirmed breast cancer with ER and/or PgR positive and HER2 negative status.~* 2. Locally advanced or metastatic breast cancer not deemed amenable to curative surgery or curative radiation therapy~* 3. HR+/HER2-~  1. HR+: ER+ or PR+ test before or up to 60 days after MBC diagnosis~ 2. HER2-: any HER2 negative test and the absence of a positive test (IHC positive 3+, FISH positive/amplified, Positive NOS) before or up to 60 days after MBC diagnosis~* 4. Female or male patients \> 18 years~* 5. Have received at least one dose of palbociclib~* 6. At least 2 document clinical visits~* 7. Treatment with palbociclib should have started from November 2017 to November 2019~* 8. Data from the clinical records should be available.~* 9. Patients must be able to understand and sign informed consent if alive.~Exclusion Criteria:~* 1. Previous treatment with hormonal therapy, targeted therapy or chemotherapy for metastatic disease. Previous anticancer treatment for early breast cancer are allowed.~* 2. Treatment with palbociclib in clinical trial or compassionate use programs~* 3. HER2 + (IHC 3+ or FISH +) tumors in the most recent or previous biopsies~* 4. HR negative tumors in the most recent biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Managing Diabetes to Gain Opportunities for a More Active Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 65 years and older~* Diagnosis of Type 2 Diabetes~* Enrolled in MyChart (University of Chicago Patient Portal)~* Outpatient clinic visit in the prior year~Exclusion Criteria:~* Under 64 years of age~* No type 2 diabetes~* Not enrolled in MyChart~* No outpatient clinic visit in the prior year

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
- Delayed Intervention/Control (Type: ACTIVE_COMPARATOR): Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete